Medicaid now covers genetic testing for children with rare diseases
H.R. 7118 — Genomic Answers for Children’s Health Act of 2026 · Filed by Scott Peters (D-CA) · 24 cosponsors · Introduced Jan 15, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires Medicaid to cover whole genome and whole exome sequencing tests for children suspected of having genetic disorders, rare diseases, or conditions of unknown origin—including developmental delays and intellectual disabilities. It mandates that these tests be paid separately (not bundled with other services), requires HHS to conduct outreach and education to ensure families and providers know about the benefit, and directs the Comptroller General to study implementation, access barriers, and health outcomes over two years.
Why we flagged it
The bill amends the Social Security Act to mandate Medicaid coverage of whole genome and whole exome sequencing for children with suspected genetic disorders or rare diseases. It is fundamentally a healthcare access and coverage expansion, not a commemorative or vanity measure.
What the text implies
- Mandating separate payment for genomic sequencing (not bundled) may increase total Medicaid expenditures and shift cost burden to state budgets, potentially affecting other Medicaid services.
- The bill requires HHS to convene stakeholders and publish implementation reports, creating ongoing administrative and coordination obligations that may slow rollout or create compliance friction.
The full analysis lists 5 implications of this text.
Who stands to gain
genomic sequencing laboratories; genetic testing companies; biopharmaceutical firms developing rare disease treatments